Inhibrx positive updated Phase 1/2 data in colorectal cancer, plans FDA talks on registrational trial
Inhibrx Biosciences posts positive updated Phase 1/2 data for ozekibart plus FOLFIRI in colorectal cancer, plans FDA talks on registrational trial
- Updated interim data show 20% objective response rate with ozekibart (INBRX-109) plus FOLFIRI in heavily pretreated colorectal cancer patients.
- Combination reported 5.5-month median progression-free survival and 87% disease control rate in Phase 1/2 study.
- Company will seek FDA feedback on first-line registrational trial design and potential accelerated pathways.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.